Separate ownership from legal accountability
A joint venture may divide capital, board control, profit and intellectual property between partners. Regulators, however, look for clearly accountable legal manufacturers, healthcare operators, importers, authorised representatives and licence holders. Those roles cannot be left as an informal understanding between shareholders.
Before incorporation, the partners should map each regulated role, the jurisdiction in which it exists and the individual or entity authorised to sign, release, report and recall.
Define the quality-system boundary
The JV may own the site while a technology partner owns formulation, master documentation or product registrations. This creates interfaces for change control, supplier approval, complaint handling, vigilance, batch release and audit access. If either party can change a critical input without the other party’s controlled approval, the operating model is incomplete.
A quality agreement should state record ownership, retention periods, escalation rules, audit rights, deviation handling and post-market responsibilities.
Protect continuity beyond the partnership
Investors should test what happens if the technology owner exits, a licence expires, a key supplier changes or the local partner loses qualified personnel. Access to equipment is not enough. Continued operation may depend on controlled documents, software credentials, reference materials, training rights and regulatory data.
The transaction model should include transition assistance, document escrow where appropriate, replacement-supplier qualification and rights to maintain already transferred processes.
Make governance executable
Board reserved matters should align with regulated decisions. Portfolio additions, capacity changes, facility modifications, new markets and subcontracting can all trigger regulatory work. A governance calendar that ignores these triggers creates delay and dispute.
The feasibility package should include a RACI matrix, regulatory cost envelope, approval critical path and dispute-escalation route before final capital commitment.
Investor checklist
- Licensed roles assigned to named legal entities
- Quality agreement aligned with shareholder agreement
- Technology and dossier access rights defined
- Exit and continuity provisions tested
- Regulatory changes included in reserved matters
This briefing is a decision framework, not legal, regulatory or financial advice. Requirements vary by jurisdiction, product and facility scope. Certification and market authorisation remain subject to competent-authority decisions.
Review a JV regulatory operating model
Translate the briefing into a project-specific scope, responsibility map and feasibility workplan.